Article in Cancer immunology research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Theodore S NowickiDivision of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, California.ORCID 0000-0002-3815-6137
Cole W PetersDivision of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, California.ORCID 0000-0001-7052-1432
Crystal QuirosDivision of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, California.ORCID 0000-0003-4635-849X
Conner K KiddDivision of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, California.ORCID 0000-0002-0152-2877
Moe KawakamiDivision of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, California.ORCID 0009-0008-6981-8114
Alexandra M KlomhausDepartment of General Internal Medicine and Health Services Research, University of California, Los Angeles, California.ORCID 0000-0002-7676-3595
Ignacio Baselga-CarreteroDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California.ORCID 0000-0003-0229-4690
Paula Kaplan-LefkoDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California.ORCID 0009-0001-9210-6421
Mignonette H MacabaliDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California.ORCID 0009-0007-9861-7234
Ivan Perez GarcilazoDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California.ORCID 0000-0002-4690-3905
Beata Berent-MaozDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California.ORCID 0000-0002-5972-9029
Begoña Comin-AnduixJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.ORCID 0000-0002-3618-9533
Antoni RibasJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.ORCID 0000-0003-3669-8458
Funding
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Project 3: Modeling and overcoming resistance to melanoma immunotherapyP01CA244118 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORICEAU, GATIEN P · 2020 to 2024
$12.8M
Next Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4M
Functional epigenomics of transgenic cellular immunotherapies for cancerK08CA241088 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NOWICKI, THEODORE SCOTT · 2021 to 2025
Transgenic T-cell receptor (TCR) T cell-based adoptive cell therapies for solid tumors are associated with dramatic initial response rates, but there remain many instances of treatment failure and disease relapse. The association of infusion product cytokine profiles with clinical response has not been explored in the context of TCR T-cell therapy products. Single-cell antigen-dependent secretomic and proteomic analysis of preinfusion clinical TCR T-cell therapy products revealed that TNFα cytokine functionality of CD8+ T cells and phospho-STAT3 signaling in these cells were both associated with superior clinical responsiveness to therapy. By contrast, CD4+ T-helper 2 cell cytokine profiles were associated with inferior clinical responses. In parallel, preinfusion levels of IL15, Flt3-L, and CX3CL1 were all found to be associated with clinical response to therapy. These results have implications for the development of therapeutic biomarkers and identify potential targets for enrichment in the design of transgenic TCR T-cell therapies for solid tumors.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Infusion Product TNFα, Th2, and STAT3 Activities Are Associated with Clinical Responses to Transgenic T-cell Receptor Cell Therapy. · full record | OpenQuestion